In HER2-negative breast cancer, EGFR signaling activation by Ano1 may contribute to breast cancer tumorigenesis, and thus Ano1 inhibition by tamoxifen may result in good prognosis in HER2-negative patients receiving tamoxifen treatment. Here, EGFR is linked to breast cancer.